Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir
Ditte Marie Kirkegaard-Klitbo, Magda Teresa Thomsen, Marco Gelpi, Flemming Bendtsen, Susanne Dam Nielsen, Thomas Benfield
Abstract
Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.
Topics & Concepts
RaltegravirElvitegravirMedicineSteatosisStavudineIntegrase inhibitorClinical trialVirologyInternal medicineHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyLiver Disease Diagnosis and TreatmentHepatitis C virus researchLiver Disease and Transplantation